Investor Relations

Corporate Profile

We are a biopharmaceutical company focused on harnessing powerful biology underlying major diseases to develop transformative therapeutics for patients.

We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines.

We aspire to operate one of our industry’s most productive research and development engines and have built a robust pipeline of drug candidates – several of which are in clinical development – to address a spectrum of large, unmet medical needs. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. However, we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News and Events

Press Releases

  • 03/04/21

    NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results

    Read more
  • 03/02/21

    NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer

    Read more
  • 02/25/21

    NGM Bio to Present at the Cowen 41st Annual Health Care Conference

    Read more

Events

  • More events are coming soon.

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Top